Developing and commercializing specialized therapies for the treatment of rare diseases by using the patient’s own blood
Latest NewsView all
EryDel Appoints Dr Esin Kosal, PhD,as Senior Vice President, Global Regulatory ...
November 30, 2020Read more
EryDel Appoints Carlo Incerti, MD, as Chairman of its Board of ...
November 20, 2020Read more
EryDel’s proprietary platform technology is an easy to use, fast and automatic bedside procedure, to encapsulate small and large molecules including therapeutic enzymes in patients’ red blood cells. The cells are immediately re-infused into patients providing prolonged half-life in circulation, reduced immunogenicity, better tolerability and predictable vascular distribution.Discover